Biotech Values

[masterlongevity]

" The FDA will shift from being a gold standard to a late adopter as companies will focus on getting to markets outside of the United States first because of the complexity and challenge at the FDA. [Comments?] "

I highly doubt this, at least in the near future. The FDA is by far the easiest agency to work with and the fastest for drug approvals. The EMEA is slower and the reimbursement situation in the EU makes getting profit slower. Other regions are even more difficult (e.g japan PMDA).